Revolutionizing Prostate Cancer Diagnosis: Center for Advanced Urology Introduces Promaxo MRI-Guided Biopsy — the First in the Philadelphia Area
A New Era in Precision Prostate Care
Prostate cancer remains one of the most common cancers among men, yet early detection continues to rely heavily on biopsy accuracy. Traditional prostate biopsies, performed with ultrasound guidance alone, often miss up to 30–40% of clinically significant cancers. Even MRI–ultrasound fusion biopsies — which overlay MRI images onto ultrasound in real time — are limited by registration errors and reliance on static, pre-recorded MRI scans.
The Center for Advanced Urology is proud to be the first practice in the Philadelphia region to introduce the Promaxo MRI-Guided Biopsy System — the only FDA-cleared, in-office, real-time MRI platform that enables truly live, MRI-directed prostate biopsies without the constraints of a hospital MRI suite.
How Promaxo Works — The Science Behind the Precision
Promaxo is a low-field MRI (0.1 Tesla) system that integrates live MRI imaging directly into the biopsy workflow. Unlike traditional MRI fusion biopsy, which uses a previously acquired MRI and fuses it with real-time ultrasound, Promaxo provides real-time MRI targeting during the actual biopsy.
This means:
- No pre-fusion error: The prostate is imaged and sampled simultaneously — eliminating the 'misalignment drift' that occurs when static MRI images are fused with ultrasound weeks later.
- True real-time visualization: The urologist can see the lesion as the biopsy needle enters, ensuring accurate sampling of the target area.
- AI-assisted targeting: Promaxo’s proprietary image registration algorithms continuously adjust for prostate motion and deformation, maintaining precise alignment throughout the procedure.
- Magnetic resonance without confinement: Its open, low-field design avoids the claustrophobic experience of traditional MRI scanners, improving patient comfort and accessibility.
Peer-reviewed studies have demonstrated that real-time MRI-guided biopsy increases cancer detection rates of Gleason 7 and higher tumors by up to 70% compared to systematic TRUS biopsy, and improves lesion concordance compared to conventional MRI fusion methods.
Comparing Biopsy Technologies
| Feature | Traditional TRUS Biopsy | Standard MRI Fusion Biopsy | Promaxo Real-Time MRI Biopsy |
|---|---|---|---|
| Imaging modality | Ultrasound only | Static MRI fused with ultrasound | Live MRI visualization |
| Accuracy | Random sampling | Moderate (fusion drift possible) | Highest accuracy with real-time targeting |
| Environment | Office | Hospital or surgical suite | Office-based, compact MRI unit |
| Anesthesia | Local | Local or sedation | Local only (no sedation required) |
| Detection rate of significant cancer | ~55–60% | ~70% | Up to 90% in targeted lesions |
| Patient comfort | Moderate discomfort | Requires transfer between MRI and biopsy | Seamless, open design and minimal downtime |
| Radiation exposure | None | None | None (MRI-based) |
The Clinical Advantage: Real-Time MRI = Real-Time Confidence
Unlike fusion biopsies that rely on alignment between separate MRI and ultrasound sessions, Promaxo allows real-time imaging feedback. This capability provides three key benefits:
1. Enhanced Targeting Accuracy — Promaxo visualizes the lesion during needle insertion, enabling millimeter-level precision. This is especially critical for small or anterior-zone tumors that are often missed by ultrasound or standard fusion methods.
2. Reduced Sampling Error — Because Promaxo provides continuous MRI imaging during the procedure, each core sample can be verified for correct spatial targeting — minimizing false negatives and the need for repeat biopsies.
3. Improved Pathologic Correlation — Pathologists receive accurately localized tissue samples, allowing for precise mapping of cancer grade and distribution, which informs more tailored treatment planning (active surveillance, focal therapy, or surgery).
Patient-Centered, Office-Based Innovation
The Promaxo biopsy is performed right in our Moorestown office, under local anesthesia, and takes approximately 45 minutes.
Patients appreciate:
- No hospital scheduling or pre-authorization delays
- No exposure to large MRI magnets or contrast agents
- A quiet, open MRI environment with minimal claustrophobia
- Same-day discharge and rapid recovery
This shift from hospital to in-office precision diagnostics aligns with modern urology’s emphasis on patient convenience, lower costs, and improved safety — while maintaining the highest standard of imaging accuracy.
The First in the Philadelphia Region
By adopting Promaxo, the Center for Advanced Urology becomes the first and only urology practice in the Greater Philadelphia area — and one of a select few nationwide — to offer real-time MRI-guided prostate biopsy. This distinction reflects our commitment to innovation, precision medicine, and patient-centered care across every stage of prostate health management.
Beyond Diagnosis: The Future of Precision Urology
As part of our comprehensive prostate program, Promaxo integrates seamlessly with:
- Multiparametric MRI (mpMRI) analysis
- Genomic testing (Decipher®, Oncotype DX®, Prolaris®)
- Active surveillance and focal therapy planning
- Advanced prostate cancer treatment strategies
By combining real-time MRI guidance with molecular and genomic insights, we’re redefining how prostate cancer is detected, classified, and treated — earlier, smarter, and more precisely than ever before.
Schedule Your Consultation
If you’ve been advised to undergo a prostate biopsy, or you’re seeking a more accurate and less invasive diagnostic experience, ask about our Promaxo real-time MRI-guided prostate biopsy today.
Center for Advanced Urology – Moorestown & Salem, NJ
Visit: www.centerforadvancedurology.com
Call: (856) 339-4466
Request Appointment: Contact Us
